NASDAQ:FGEN - FibroGen Stock Price, Forecast & News

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen Inc (NASDAQ:FGEN) issued its quarterly earnings data on Monday, November, 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the Zacks' consensus estimate of ($0.59) by $0.02. The biopharmaceutical company earned $33.17 million during the quarter, compared to the consensus estimate of $31.61 million. FibroGen had a return on equity of 7.33% and a net margin of 11.81%. The firm's revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.50) EPS. View FibroGen's Earnings History.

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for FibroGen.

FibroGen will be holding an earnings conference call on Monday, March 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 equities research analysts have issued twelve-month price targets for FibroGen's stock. Their forecasts range from $40.00 to $72.00. On average, they anticipate FibroGen's share price to reach $52.33 in the next year. This suggests a possible upside of 25.2% from the stock's current price. View Analyst Price Targets for FibroGen.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.

Press coverage about FGEN stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. FibroGen earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for FibroGen.

FibroGen saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 5,580,000 shares, an increase of 10.3% from the January 15th total of 5,060,000 shares. Based on an average trading volume of 825,000 shares, the short-interest ratio is presently 6.8 days. Approximately 7.2% of the shares of the stock are sold short. View FibroGen's Current Options Chain.

Some companies that are related to FibroGen include Genmab A/S (GNMSF), Teva Pharmaceutical Industries (TEVA), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO) and Jazz Pharmaceuticals (JAZZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), ALJ Regional (ALJJ) and Transocean (RIG).

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (10.81%), Janus Henderson Group PLC (3.03%), State Street Corp (3.02%), Farallon Capital Management LLC (1.55%), First Trust Advisors LP (1.50%) and Bank of New York Mellon Corp (1.31%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., State Street Corp, Handelsbanken Fonder AB, Strs Ohio, Rafferty Asset Management LLC, Citigroup Inc., Bank of America Corp DE and Bank of Montreal Can. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo and Thomas B Neff. View Insider Buying and Selling for FibroGen.

FGEN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Farallon Capital Management LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Credit Suisse AG, Man Group plc, AQR Capital Management LLC and Assenagon Asset Management S.A.. View Insider Buying and Selling for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $41.80.

FibroGen has a market capitalization of $3.65 billion and generates $212.96 million in revenue each year. The biopharmaceutical company earns $-86,420,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. FibroGen employs 461 workers across the globe.View Additional Information About FibroGen.

The official website for FibroGen is http://www.fibrogen.com/.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]